Migraine Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 6.16 Billion |
| Market Size (2029) | USD 8.58 Billion |
| CAGR (2024 - 2029) | 6.84 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Migraine Therapeutics Market Analysis
The Global Migraine Therapeutics Market size is estimated at USD 6.16 billion in 2024, and is expected to reach USD 8.58 billion by 2029, growing at a CAGR of 6.84% during the forecast period (2024-2029).
COVID-19 was a global public health crisis, and it impacted almost every industry, and its long-term effects were expected to affect industry growth over the forecast period. According to the study titled "Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users" published in BMC neurology in September 2021, although the number of migraine attacks decreased, the proportion of stress-related migraine attacks peaked at 53% during COVID-19. Also, the study titled "COVID-19 and Headache Medicine: A Narrative Review of NonSteroidal AntiInflammatory Drug (NSAID) and Corticosteroid Use" published in July 2021, reported that there may be an increase in the number of patients with headaches as their primary complaint during the COVID19 pandemic. Hence, COVID-19 had a significant impact on the migraine therapeutics market.
Growing awareness about migraine and treatment options, rising R&D spending leading to massive pipeline products, and an increase in the prevalence of migraines with high unmet needs are all contributing to the global growth of the migraine therapeutics market.
The various strategic activities by the key market players, such as product launches and product approvals, as well as mergers and acquisitions, boost the market over the forecast period. For instance, in March 2022, AbbVie reported a positive phase 3 progress trial evaluating atogepant (QULIPTA in the United States) for the preventive treatment of chronic migraine in adults. It is an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant). In the trial, the drug met its primary endpoint of a statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily (QD) and 30 mg twice daily (BID) doses, across the 12-week treatment period.
Additionally, in September 2021, the United States Food and Drug Administration (FDA) approved QULIPTA (atogepant) to AbbVie for the prevention of episodic migraine in adults. QULIPTA is one of the world's first and only oral calcitonin gene-related peptide (CGRP) receptor antagonists (gepant) developed specifically for migraine prevention.
Thus, the market is expected to project growth over the forecast period. However, the growth of the migraine therapeutics market may be hampered due to a lack of proper diagnosis, undiagnosed cases, and drug side effects over the forecast period.
Migraine Therapeutics Market Trends
This section covers the major market trends shaping the Migraine Therapeutics Market according to our research experts:
The Triptans Segment Is Expected to Grow at a Healthy CAGR Over the Forecast Period
Triptans are a newer class of drug that increases serotonin levels in the brain, reducing inflammation and constricting blood vessels, effectively ending a migraine. Triptans constrict blood vessels in the brain and block pain pathways. These ergotamines are more migraine-specific than previous ergotamines. Almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan (Imitrex), sumatriptan and naproxen (Treximet), and zolmitriptan (Zomig) are some of the triptans available. Sumatriptan and naproxen sodium (Treximet), a single-tablet combination, are more effective than either medication alone in alleviating migraine symptoms.
Furthermore, as per the study titled "Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine" published in JAMA Network in October 2020, ditans and gepants were associated with less efficacy compared with triptans, whereas gepants were associated with fewer adverse events compared with triptans. Thus, due to the higher efficacy of the triptans, there is expected to be a rise in demand for them, thereby boosting the segment over the forecast period.
Moreover, the product launches and market approvals for drugs in the triptan class are also driving the growth of the market segment. For instance, in January 2020, Eli Lilly and Company launched the REYVOW (lasmiditan) C-V 50 mg and 100 mg tablets. It is an oral medication for the acute treatment of migraine with or without aura in adults.
Thus, owing to the aforementioned factors such as the higher efficacy of triptan and new product launches, the market segment is expected to boost the market over the forecast period.
North America is Expected to Hold a Significant Share Over the Forecast Period
North America is expected to dominate the overall market and is projected to maintain its dominance over the coming years. The high prevalence of migraine, the increasing adoption of novel therapeutics, and the large target population in the United States are the factors that contribute to the region's dominance.
According to the article titled "What is Migraine?" published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, such a high prevalence is expected to boost the migraine therapeutics market in the United States.
Additionally, various strategic activities by key market players, such as product launch and approval, as well as mergers and acquisitions, will boost the market growth. For instance, in February 2020, Lundbeck received VYEPTI (eptinezumab-jjmr) approval by the United States Food and Drug Administration (FDA) for the preventive treatment of migraine in adults. Furthermore, in May 2021, Biohaven Pharmaceutical Holding Company Ltd. received United States Food and Drug Administration (FDA) approval for NURTEC ODT (rimegepant 75 mg) for the preventive treatment of migraine. NURTEC ODT is indicated for adult patients with episodic migraine, e.g., those who experience fewer than 15 headache days per month. Such approvals propel the growth of the studied market over the forecast period.
Thus, owing to the abovementioned factors, the North American region is expected to dominate the market over the forecast period.
Migraine Therapeutics Industry Overview
The migraine therapeutics market is moderately fragmented with the presence of a large number of local and international players. Key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key market players include Amgen, Teva Pharmaceutical, Eli Lilly and Company, and GlaxoSmithKline plc, among others.
Migraine Therapeutics Market Leaders
-
Amgen
-
Teva Pharmaceutical Industries Ltd
-
GlaxoSmithKline
-
Eli Lilly and Company
-
Bausch Health
*Disclaimer: Major Players sorted in no particular order
Migraine Therapeutics Market News
- In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
- In January 2022, BioDelivery Sciences launched a new drug, Elyxyb (celecoxib oral solution), a fast-acting liquid. It is one of the first Food and Drug Administration-approved ready-to-use oral solutions for adults in the acute treatment of migraine, with or without aura.
Migraine Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Awareness about Migraine and its Treatment Options
- 4.2.2 Increasing R&D Expenditures Leading to High Pipeline Products
- 4.2.3 Increasing Prevalence of Migraines along with High Unmet Needs
-
4.3 Market Restraints
- 4.3.1 Adverse Effects of Drugs
- 4.3.2 Lack of Proper Diagnosis and Increasing Undiagnosed Cases
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Therapeutics
- 5.1.1 Pain-relieving Medications
- 5.1.1.1 Analgesics
- 5.1.1.2 Triptans
- 5.1.1.3 Ergot Alkaloids
- 5.1.1.4 Others
- 5.1.2 Preventive Medications
- 5.1.2.1 Blood pressure-lowering Medications
- 5.1.2.2 Anticonvulsant Drugs
- 5.1.2.3 Calcitonin Gene-related Peptide (CGRP) Antagonists
- 5.1.2.4 Other Preventative Therapies
-
5.2 By Route of Administration
- 5.2.1 Oral & Nasal
- 5.2.2 Injectables
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Amgen
- 6.1.2 Abbvie Inc.
- 6.1.3 AstraZeneca
- 6.1.4 Eli Lilly and Co.
- 6.1.5 GlaxoSmithKline
- 6.1.6 Merck & Co., Inc.
- 6.1.7 Pfizer
- 6.1.8 Bausch Health
- 6.1.9 Teva Pharmaceuticals
- 6.1.10 Novartis AG
- 6.1.11 Eisai Co., Ltd.,
- 6.1.12 Abbott Laboratories
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Migraine Therapeutics Industry Segmentation
As per the scope of the report, migraine is a complex neurological condition characterized by frequent headaches that can last from 4 to 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances. The Migraine Therapeutics Market is segmented by Therapeutics (Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)), Route of Administration (Oral & Nasal and Injectables), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Therapeutics | Pain-relieving Medications | Analgesics |
| Triptans | ||
| Ergot Alkaloids | ||
| Others | ||
| By Therapeutics | Preventive Medications | Blood pressure-lowering Medications |
| Anticonvulsant Drugs | ||
| Calcitonin Gene-related Peptide (CGRP) Antagonists | ||
| Other Preventative Therapies | ||
| By Route of Administration | Oral & Nasal | |
| Injectables | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Migraine Therapeutics Market Research FAQs
How big is the Global Migraine Therapeutics Market?
The Global Migraine Therapeutics Market size is expected to reach USD 6.16 billion in 2024 and grow at a CAGR of 6.84% to reach USD 8.58 billion by 2029.
What is the current Global Migraine Therapeutics Market size?
In 2024, the Global Migraine Therapeutics Market size is expected to reach USD 6.16 billion.
Who are the key players in Global Migraine Therapeutics Market?
Amgen, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, Eli Lilly and Company and Bausch Health are the major companies operating in the Global Migraine Therapeutics Market.
Which is the fastest growing region in Global Migraine Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Migraine Therapeutics Market?
In 2024, the North America accounts for the largest market share in Global Migraine Therapeutics Market.
What years does this Global Migraine Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Global Migraine Therapeutics Market size was estimated at USD 5.77 billion. The report covers the Global Migraine Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Migraine Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Migraine Therapeutics Industry Report
Statistics for the 2024 Migraine Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Migraine Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
